

## Fagron CEO Ger van Jeveren steps down Board of Directors appoints Hans Stols as successor

Further to the press release of 30 November 2015, the Board of Directors has further analyzed the various strategic options for Fagron. The Board of Directors has decided to no longer give priority to a takeover process and instead give its full attention to its discussions with financing banks and a possible public or private capital increase. The talks with the banks are progressing constructively and Fagron expects to be able to make further announcements on this matter shortly.

In light of the outcome of this strategic analysis the current CEO, Ger van Jeveren, has decided to resign and is stepping down as managing director and CEO of Fagron with immediate effect. The Board of Directors has decided unanimously, on the advice of the nomination and remuneration committee, to appoint Hans Stols, a current independent director of Fagron, as CEO with immediate effect. Mr. Stols's curriculum vitae is attached as appendix to this press release.

**Robert Peek, chairman of the Board of Directors of Fagron:** "Mr. Van Jeveren founded Fagron in 1990 and created a world-class player based on a clear vision and strategy, that is currently active in 32 countries across five continents. The Board of Directors and all employees of Fagron are extremely grateful to Ger for his relentless involvement and efforts to develop Fagron and help all patients across the globe who benefit from pharmaceutical compounding. The Board of Directors wishes his successor, Mr. Hans Stols, success as Fagron's new CEO."

**Hans Stols, CEO of Fagron:** "The leading market positions, the highly qualified employees, the innovative strength, the streamlined organization and a growing demand for tailor-made medication provide an important foundation for the further growth of Fagron. However, the trust of our shareholders, investors and financiers is currently my main priority. The talks with our banks and investors are progressing constructively and I therefore expect to be able to provide the market with further information in the short term."

*In the event of any discrepancies between the English translation and the original Dutch version, of this press release, the latter shall prevail.*

### For more information:

Constantijn van Rietschoten  
Chief Marketing Officer / Investor Relations a.i.  
Tel. +31 6 53 69 15 85  
[constantijn.van.rietschoten@fagron.com](mailto:constantijn.van.rietschoten@fagron.com)

### Fagron profile

Fagron is a scientific pharmaceutical R&D company that is focused on optimizing and innovating customized pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.

The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

<sup>1</sup> This press release was sent out by Fagron NV and Fagron BV.



### Hans Stols (1959)

Hans Stols has held various positions at the Rijksaccountantsdienst, ABN-AMRO Bank NV and Stada Arzneimittel AG. Until 2006 Mr. Stols was Chief Operational Officer and member of the Board of Directors of Stada Arzneimittel AG and was founding member of the board of many Stada subsidiaries. Mr. Stols also provides consulting services to many corporations, including Stada Arzneimittel AG and Goldman Sachs London (ad hoc) and has, among other things, been chairman of the European Generic Medicine Association, Vereniging Euro Specialite's and Nederlandse Cystic Fibrosis Stichting.

